BioGlue is a surgical adhesive widely used to help reinforce complex cardiac and vascular repairs. Since its introduction, several case reports have emerged revealing complications that all providers should be mindful of whenever the product is used. This report considers a unique situation where BioGlue was used after double cardiac valve repair that resulted in adhesion of the new mechanical aortic valve leaflets and was difficult to visualize with transesophageal echocardiography.
Introduction
Since its approval by the Federal Drug Administration (FDA) in 2001, 1 BioGlue surgical adhesive (CryoLife, Inc, Kennesaw, GA) has been widely used to help obtain hemostasis in various cardiac and vascular surgical repairs. Able to be stored at room temperature for up to 3 years, BioGlue is a 2-part solution composed of purified bovine serum albumin and glutaraldehyde. These interact to rapidly initiate polymerization within 20 to 30 seconds, with maximal bonding to both native and prosthetic structures occurring in 2 to 3 minutes, and thereafter achieving relatively high tensile and shear strengths. 2 These properties make BioGlue seem like an ideal method to reinforce surgical repairs. In fact, its use has been shown to reduce anastomotic bleeding, lower pledglet use, and lower overall short-term neurological events in the BioGlue group. 3 However, its use has not demonstrated any difference in mortality, intensive care unit length of stay, transfusion requirements, rate of cerebrovascular accident, or myocardial infarction. 3 BioGlue gained early acceptance in practice as an adjunct in complex acute dissecting aortic aneurysm repairs, 4 but also began to be used in repair of fragile aortic structures and in securing suture lines following replacement of cardiac valves. 2 However, despite its welldescribed efficacy and popularity, BioGlue has limitations. It requires a bloodless surgical field for proper application, and may be difficult to control due to low viscosity. In addition, it becomes less compliant than other sealants, which thus may restrict movement (such as stricture formation if applied circumferentially), and may trigger local glutaraldehyde tissue toxicity. 2 BioGlue application astray from the intended site has the potential to cause mass effects, lead to embolic events, and adhere structures in a manner that might inhibit function. In this report, we present such a case that was uniquely complicated by difficult detection of the incident by standard means of intraoperative monitoring.
Case
Our patient was a 28-year-old male who was 6 years statuspost mitral valve replacement for endocarditis, who presented with severe mitral stenosis and moderate mitral regurgitation. The decision was made to proceed with mitral valve replacement with a mechanical valve. Preoperative left heart catheterization revealed mean mitral valve gradient of 20 mm Hg, mitral valve area of 1.3 cm , left ventricular ejection fraction (LVEF) of 40% to 45%, and a normal trileaflet aortic valve. Clearance of extensive adhesions led to friability of left atrial tissue and the aortomitral curtain, which tore upon seating of the mechanical mitral valve, requiring repair with a bovine pericardial graft. After the repair of the aortomitral curtain, the aortic valve was inspected by the surgeons, and the noncoronary cusp of the aortic valve was noted to be retracted, although no suture material was visualized that might have caused it. Thus, the aortic valve was replaced with a mechanical aortic valve. This required a root enlargement due to the small nature of the patient's aorta, and a 19-mm mechanical valve was placed. On closure of the aorta, the aortotomy suture line was further sealed using BioGlue. On initial attempt to wean from cardiopulmonary bypass (CPB), at least moderate aortic stenosis (AS) and severe aortic insufficiency (AI) of the new valve were detected via TEE, but visualization was exceptionally difficult due to sonographic shadowing by the new mechanical mitral valve in the mid-esophageal views (see Videos 1 and 2). Even the deep transgastric view proved to be difficult due to the adjacent suture lines in the aortic root (see Figure 1) , and the etiology of the combined AS and AI was not clear. We were concerned for some type of outflow obstruction, but again, were unable to definitively comment whether the new aortic valve was functioning properly as the leaflets were not seen to open. Epicardial ultrasound was then utilized, but the etiology and degree of the AS and AI remained unclear. Despite the inability to clearly visualize anatomical structures, measurements made include: mean pressure gradient 33 mm Hg, maximal pressure gradient 61 mm Hg, estimated aortic valve area as low as 0.59 cm 2 , and pressure half-time of 178 ms (see Figures 2 and 3) . After much discussion, we asked the perfusionist to leave volume in the heart to better evaluate the valve, but the pulmonary artery pressures rose precipitously and the visualization was still poor. Therefore, the patient underwent recooling for a second aortic cross-clamp to directly reevaluate the aortic valve. On surgical inspection, it became clear that the leaflets of the aortic valve had been frozen in a semiclosed position by BioGlue. At this point, the newly implanted and now damaged aortic valve was removed and replaced with another 19-mm mechanical valve. The aortotomy site was then again sutured but was not reinforced with BioGlue a second time. In response to hemodynamic instability, an intra-aortic balloon pump was then placed to facilitate separation from CPB. Total CPB time was 529 minutes and aortic cross-clamp time was 320 minutes. Post-CPB, mechanical mitral and aortic valves were well seated without residual stenosis or insufficiency, and LVEF was 30% to 35%. Postoperatively, the patient was extubated on postoperative day 4 and discharged on postoperative day 14, at which time his LVEF was 50% to 55% without support. Perioperatively, the patient suffered an ischemic left MCA stoke, possibly due to the additional BioGlue embolization, but he has had gradual improvement of symptoms and is now at home and ambulatory.
Discussion
Since preliminary studies funded by CryoLife, Inc, demonstrating the efficacy of BioGlue, and the widespread application of BioGlue in numerous surgeries, case reports describing BioGlue complications have been accumulating. Previous case reports of BioGlue-associated dysfunction of newly placed mechanical heart valves have been described. [5] [6] [7] [8] [9] [10] [11] Although presumed to be a rare event, it is difficult to know the actual incidence of such complications, as they are likely underreported. As with our case, most previous reports have described a situation wherein hemodynamic instability was encountered on attempted wean from CPB, which led to reinitiation of cardioplegia for subsequent repair. There was one report where valvular dysfunction was not recognized until postoperative day 5, which then prompted return to the operating room for repair. 11 Our case is the first to report wherein both mitral and aortic valves were replaced and acted together to completely obliterate visualization of aortic valve leaflets across all TEE views.
As part of monitoring considered standard in most cardiac procedures, 12 intraoperative TEE was utilized in our case before and after CPB to guide management decisions. As in previous cases, acoustic shadowing imposed by the newly implanted prosthetic valve established an artifactual "blind spot" limiting accurate visualization of anatomic structures located behind them. 13 This situation complicates echocardiographic diagnosis of anatomic pathology in the obscured region and thus detection must instead be inferred by other means, such as hemodynamics or surface echocardiography. It has been suggested that supplementation of TEE in similarly confusing situations with fluoroscopy might permit earlier detection and diagnostic certainty, although its role has not been critically elucidated. 10, 11, 13 Manufacturer instructions and indications for proper use of BioGlue are strict. 1 However, even with correct application, in vitro studies of BioGlue use to secure suture lines along fresh porcine aortic grafts and prosthetic grafts demonstrated BioGlue leakage through suture holes 10% of the time, independent of suture size.
14 Most authors presenting cases of BioGlue complications continue to support its use in the appropriate surgical and patient-specific context, but offer recommendations for better outcomes, such as to turning off any intraluminal suctioning device prior to application, applying slowly to increased initial viscosity, and only applying a <2 mm layer.
7,10

Conclusion
BioGlue has certain risks that should be acknowledged prior to use. In the cardiac surgical population, complications from BioGlue should be considered in the differential diagnosis of valvular dysfunction after its use. Mechanical mitral valves and postsurgical changes may hinder adequate visualization via TEE, and thus might increase reliance on other modalities of diagnosis, including surgical inspection when absolutely necessary.
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